Company Description
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives.
It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy.
The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers.
It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells.
The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Craig W. Philips |
Contact Details
Address: 7683 Se 27th Street, Suite 481 Mercer Island, Washington 98040 United States | |
| Phone | (206) 378-0400 |
| Website | kinetabio.com |
Stock Details
| Ticker Symbol | KA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001445283 |
| CUSIP Number | 49461C102 |
| ISIN Number | US49461C1027 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig W. Philips | President |
| Pauline Kenny Esq., J.D. | Advisor |
| Keith A. Baker | Chief Financial Officer |
| Dr. Thierry Guillaudeux Ph.D. | Chief Scientific Officer |
| Gary Gentges | Executive Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 8-K | Current Report |
| May 30, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | 8-K | Current Report |
| May 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 24, 2024 | 8-K | Current Report |